Related Experiment Videos
COX-2 expression during early lung squamous cell carcinoma oncogenesis
C Mascaux1, B Martin, J-M Verdebout
1Dept of Intensive Care and Thoracic Oncology, CHU Saint-Pierre, Brussels, Belgium. celine.mascaux@bordet.be
The European Respiratory Journal
|August 2, 2005
Summary
Cyclooxygenase (COX)-2 expression increases in precancerous lesions of the lung. This finding suggests COX-2 may serve as an early biomarker for squamous cell carcinoma development in high-risk patients.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Cyclooxygenase (COX)-2 is linked to cancer development and is a target for cancer prevention.
- Increased COX-2 expression in non-small cell lung cancer correlates with poor prognosis.
Purpose of the Study:
- To investigate COX-2 expression in normal bronchial epithelium and precancerous lesions of squamous cell carcinoma.
- To determine if COX-2 can serve as an early diagnostic marker for lung cancer progression.
Main Methods:
- Immunohistochemistry was used to analyze COX-2 expression in 106 bronchial biopsies from high-risk lung cancer patients.
- Biopsies included normal epithelium, low-grade, and high-grade precancerous lesions.
Main Results:
- No increased COX-2 expression was observed in normal epithelium or low-grade lesions.
- COX-2 positivity was found in severe dysplasia, carcinoma in situ, and invasive carcinoma.
- A significant difference in COX-2 expression distinguished low-grade from high-grade lesions, with a 100% positive predictive value for high-grade lesions.
Conclusions:
- Bronchial precursors of squamous cell carcinoma exhibit elevated COX-2 expression.
- COX-2 expression effectively differentiates between low-grade and high-grade precancerous lesions.
- COX-2 shows potential as an early biomarker for squamous cell carcinoma.